IMC Chicago’s Myriad Genetics MYGN Stock Holding History

IMC Chicago’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$72.6K	Buy	+16,848	New	+$71.1K	﹤0.01%	6119

Other funds holding MYGN

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

OP Asset Management Helsinki $11.8B AUM 34.59% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

IMC Chicago's MYGN Position: Q3 2026 in Review

IMC Chicago opened a new position in Myriad Genetics (MYGN) in Q3 2026: 16,848 shares worth $72.6K. The stake represents ﹤0.01% of the portfolio and ranks #6119 among its holdings.

79 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.

IMC Chicago held 16,848 shares of Myriad Genetics worth $72.6K as of Q3 2026.
Myriad Genetics was a new IMC Chicago position in Q3 2026.
Myriad Genetics made up ﹤0.01% of IMC Chicago's portfolio in Q3 2026, its #6119 holding.
79 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.